[go: up one dir, main page]

WO2009072598A1 - 掻痒症治療剤 - Google Patents

掻痒症治療剤 Download PDF

Info

Publication number
WO2009072598A1
WO2009072598A1 PCT/JP2008/072142 JP2008072142W WO2009072598A1 WO 2009072598 A1 WO2009072598 A1 WO 2009072598A1 JP 2008072142 W JP2008072142 W JP 2008072142W WO 2009072598 A1 WO2009072598 A1 WO 2009072598A1
Authority
WO
WIPO (PCT)
Prior art keywords
pruritus
therapeutic agent
neutralizing antibody
mouse
clone
Prior art date
Application number
PCT/JP2008/072142
Other languages
English (en)
French (fr)
Inventor
Yoshinobu Higuchi
Keiko Kasutani
Hidetomo Kitamura
Masakazu Hasegawa
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Seiyaku Kabushiki Kaisha filed Critical Chugai Seiyaku Kabushiki Kaisha
Priority to AU2008332276A priority Critical patent/AU2008332276B2/en
Priority to BRPI0821145A priority patent/BRPI0821145B8/pt
Priority to EP08857461A priority patent/EP2241332A4/en
Priority to MX2010006097A priority patent/MX2010006097A/es
Priority to JP2009544731A priority patent/JP5475460B2/ja
Priority to CA2708065A priority patent/CA2708065C/en
Priority to RU2010127291/10A priority patent/RU2541780C2/ru
Priority to US12/746,229 priority patent/US8431127B2/en
Priority to CN200880126534.1A priority patent/CN101939025B/zh
Publication of WO2009072598A1 publication Critical patent/WO2009072598A1/ja
Priority to HK11105302.9A priority patent/HK1151226A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

　本発明者らは、ヒト抗体ファージライブラリーから、ＩＬ－３１依存性Ｂａ／Ｆ３細胞増殖アッセイ系に於いて、強い増殖抑制活性を示すクローンＢＭ０９５を得た。この抗マウスＮＲ１０中和抗体を用いて、掻痒症モデルマウスに投与したところ、顕著な症状の抑制効果が示された。抗ＮＲ１０中和抗体が掻痒症治療薬として有用であることが明らかとなった。
PCT/JP2008/072142 2007-12-05 2008-12-05 掻痒症治療剤 WO2009072598A1 (ja)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2008332276A AU2008332276B2 (en) 2007-12-05 2008-12-05 Therapeutic agent for pruritus
BRPI0821145A BRPI0821145B8 (pt) 2007-12-05 2008-12-05 uso de um anticorpo anti-nr10 como agente preventivo ou terapêutico para prurido
EP08857461A EP2241332A4 (en) 2007-12-05 2008-12-05 THERAPEUTIC AGENT AGAINST PRITURE
MX2010006097A MX2010006097A (es) 2007-12-05 2008-12-05 Agentes terapeuticos para tratar el prurito.
JP2009544731A JP5475460B2 (ja) 2007-12-05 2008-12-05 掻痒症治療剤
CA2708065A CA2708065C (en) 2007-12-05 2008-12-05 Therapeutic agent for pruritus
RU2010127291/10A RU2541780C2 (ru) 2007-12-05 2008-12-05 Терапевтическое средство от зуда
US12/746,229 US8431127B2 (en) 2007-12-05 2008-12-05 Method for treating pruritus comprising administering an NR10 antagonist
CN200880126534.1A CN101939025B (zh) 2007-12-05 2008-12-05 搔痒症治疗药
HK11105302.9A HK1151226A1 (en) 2007-12-05 2011-05-27 Therapeutic agent for pruritus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007315144 2007-12-05
JP2007-315144 2007-12-05

Publications (1)

Publication Number Publication Date
WO2009072598A1 true WO2009072598A1 (ja) 2009-06-11

Family

ID=40717776

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/072142 WO2009072598A1 (ja) 2007-12-05 2008-12-05 掻痒症治療剤

Country Status (14)

Country Link
US (1) US8431127B2 (ja)
EP (1) EP2241332A4 (ja)
JP (1) JP5475460B2 (ja)
KR (1) KR101595134B1 (ja)
CN (2) CN104162155A (ja)
AU (1) AU2008332276B2 (ja)
BR (1) BRPI0821145B8 (ja)
CA (1) CA2708065C (ja)
HK (2) HK1151226A1 (ja)
MX (1) MX2010006097A (ja)
MY (2) MY185647A (ja)
RU (2) RU2596397C2 (ja)
TW (1) TWI441649B (ja)
WO (1) WO2009072598A1 (ja)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010064697A1 (ja) * 2008-12-05 2010-06-10 中外製薬株式会社 抗nr10抗体、およびその利用
WO2011137395A1 (en) * 2010-04-30 2011-11-03 Rother Russell P Anti-c5a antibodies and methods for using the antibodies
JPWO2010064697A1 (ja) * 2008-12-05 2012-05-10 中外製薬株式会社 抗ｎｒ１０抗体、およびその利用
US8431127B2 (en) 2007-12-05 2013-04-30 Chugai Seiyaku Kabushiki Kaisha Method for treating pruritus comprising administering an NR10 antagonist
US9028821B2 (en) 2006-06-08 2015-05-12 Chugai Seiyaku Kabushiki Kaisha Method of treating an inflammatory disease comprising administering an NR 10 antibody antagonist
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US9399680B2 (en) 2007-12-05 2016-07-26 Chugai Seiyaku Kabushiki Kaisha Nucleic acids encoding anti-NR10 antibodies
US9688762B2 (en) 2007-09-26 2017-06-27 Chugai Sciyaku Kabushiki Kaisha Modified antibody constant region
US9868948B2 (en) 2008-04-11 2018-01-16 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US10253091B2 (en) 2009-03-19 2019-04-09 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US10544227B2 (en) 2015-04-14 2020-01-28 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
KR20210145295A (ko) 2015-04-14 2021-12-01 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
US11260125B2 (en) 2019-11-20 2022-03-01 Chugai Seiyaku Kabushiki Kaisha Anti-IL31RA antibody-containing formulations
WO2022049614A1 (ja) 2020-09-01 2022-03-10 中外製薬株式会社 Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9770195B2 (en) * 2012-08-09 2017-09-26 The Regents Of The University Of California Automated scratch detection system and signal processing algorithm for the study of pruritus in animals
MA42444A (fr) 2015-07-16 2018-05-23 Lilly Co Eli Traitement du prurit
CN110563844A (zh) * 2019-09-04 2019-12-13 华中农业大学 一种抗犬白介素31受体的多克隆抗体及其应用
CA3211221A1 (en) * 2021-02-22 2022-08-25 Zoetis Services Llc Horse il-31 induced pruritus model

Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP0058481A1 (en) 1981-02-16 1982-08-25 Zeneca Limited Continuous release pharmaceutical compositions
EP0133988A2 (de) 1983-08-02 1985-03-13 Hoechst Aktiengesellschaft Regulatorische Peptide enthaltende pharmazeutische Präparate mit protrahierter Freisetzung und Verfahren zu deren Herstellung
EP0239400A2 (en) 1986-03-27 1987-09-30 Medical Research Council Recombinant antibodies and methods for their production
JPH0159878B2 (ja) 1982-05-21 1989-12-20 Yunibaashitei Obu Karifuorunia
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1995001438A1 (en) 1993-06-30 1995-01-12 Medical Research Council Sbp members with a chemical moiety covalently bound within the binding site; production and selection thereof
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1998046777A1 (fr) 1997-04-11 1998-10-22 Centre National De La Recherche Scientifique (Cnrs) Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
WO2000075314A1 (fr) 1999-06-02 2000-12-14 Chugai Research Institute For Molecular Medicine, Inc. Proteine receptrice d'hemopoietine
WO2003104453A1 (ja) 2002-06-05 2003-12-18 中外製薬株式会社 抗体作製方法
WO2005005636A1 (ja) 2003-07-15 2005-01-20 Chugai Seiyaku Kabushiki Kaisha 形質転換細胞によるIｇMの産生とその定量方法
WO2006088956A2 (en) 2005-02-14 2006-08-24 Zymogenetics, Inc. Methods of predicting therpeutic response in atopic dermatitis to il-31 antagonists
WO2006088855A1 (en) * 2005-02-14 2006-08-24 Zymogenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
WO2006122079A1 (en) 2005-05-06 2006-11-16 Zymogenetics, Inc. Il-31 monoclonal antibodies and methods of use

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2898064B2 (ja) 1989-08-03 1999-05-31 忠三 岸本 ヒトｇｐ１３０蛋白質
GB9016440D0 (en) 1990-07-26 1990-09-12 Elopak Systems A laminate
BR9204244A (pt) 1992-10-26 1994-05-03 Cofap Ferro fundido cinzento
PL309249A1 (en) 1992-12-01 1995-10-02 Protein Design Labs Humanised antibodies against l-selectin
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
FR2729855A1 (fr) * 1995-01-26 1996-08-02 Oreal Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
AUPN481295A0 (en) 1995-08-16 1995-09-07 Medvet Science Pty. Ltd. Agonists of haemopoietic growth factors
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
AUPN564195A0 (en) 1995-09-26 1995-10-19 Walter And Eliza Hall Institute Of Medical Research, The A novel haemopoietin receptor and genetic sequences encoding same
ES2334408T3 (es) 1995-10-23 2010-03-09 Zenyth Operations Pty Ltd Receptor de hematopoyetina y secuencias geneticas que lo codifican.
US6642360B2 (en) * 1997-12-03 2003-11-04 Genentech, Inc. Secreted polypeptides that stimulate release of proteoglycans from cartilage
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
AU759689B2 (en) 1998-06-24 2003-04-17 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor proteins
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
EP2258849A1 (en) 1999-06-01 2010-12-08 Schering Corporation Mammalian receptor proteins; related reagents and methods
US20030082734A1 (en) * 1999-06-01 2003-05-01 Dowling Lynette M. Mammalian receptor proteins; related reagents and methods
WO2001023556A1 (fr) * 1999-09-27 2001-04-05 Chugai Seiyaku Kabushiki Kaisha Nouvelle proteine receptrice d'hemopoietine (nr12)
CN1575337A (zh) * 2000-05-10 2005-02-02 先灵公司 哺乳动物细胞因子受体亚单位蛋白、相关试剂及方法
US20030096339A1 (en) * 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
WO2002000721A2 (en) 2000-06-26 2002-01-03 Zymogenetics, Inc. Cytokine receptor zcytor17
AU2002223182B2 (en) 2000-10-06 2007-08-30 Immunex Corporation Hematopoietin receptors HPR1 and HPR2
WO2002077230A1 (fr) 2001-03-26 2002-10-03 Chugai Seiyaku Kabushiki Kaisha Variants d'epissage nr10
WO2004003140A2 (en) * 2002-01-18 2004-01-08 Zymogenetics, Inc. Cytokine receptor zcytor17 multimers
DK2230299T3 (da) 2002-01-18 2012-03-26 Zymogenetics Inc Hidtil ukendt cytokin ZCYTOR17-ligand
DK1485477T3 (da) 2002-02-25 2009-08-10 Genentech Inc Hidtil ukendt type-1-cytokinreceptor GLM-R
CA2483909A1 (en) * 2002-05-01 2003-11-13 Schering Aktiengesellschaft Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants
US7579000B2 (en) * 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
US20040223970A1 (en) * 2003-02-28 2004-11-11 Daniel Afar Antibodies against SLC15A2 and uses thereof
EP1605974B1 (en) 2003-03-04 2014-11-12 Alexion Pharmaceuticals, Inc. Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
CN103864934A (zh) 2003-03-24 2014-06-18 津莫吉尼蒂克斯公司 抗il-22ra抗体和结合伴侣以及在炎症中的使用方法
CA2572133A1 (en) 2004-06-25 2006-01-12 Medimmune, Inc. Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
EP1671642A1 (en) 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
MX2007007935A (es) 2004-12-28 2007-12-06 Innate Pharma Sa Anticuerpos monoclonales contra nkg2a.
AU2006207945B2 (en) 2005-01-28 2012-02-09 Zymogenetics, Inc. Homogeneous preparations of IL-31
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
BRPI0706487A2 (pt) 2006-01-10 2011-03-29 Zymogenetics Inc métodos de tratamento de inflamação em tecido neuronal de um mamìfero, de tratamento de dor em um mamìfero, de antagonizar transdução de sinal induzida por il-31 em células de gánglio da raiz dorsal, de tratamento de sintomas associados com queimadura, de tratamento de sintomas associados com infecção viral em um mamìfero, e, de tratamento de dor associada com doença intestinal inflamatória
KR20150091545A (ko) * 2006-06-08 2015-08-11 추가이 세이야쿠 가부시키가이샤 염증성 질환의 예방 또는 치료제
EP2032602B1 (en) * 2006-06-15 2013-03-27 The Board of Trustees of the University of Arkansas Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
ATE494306T1 (de) * 2007-02-14 2011-01-15 Vaccinex Inc Humanisierte anti-cd100-antikörper
NZ579158A (en) 2007-02-23 2012-01-12 Schering Corp Engineered anti-il-23p19 antibodies
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
EP2194066B1 (en) 2007-09-26 2016-03-09 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
MX2010003329A (es) 2007-09-26 2010-04-27 Chugai Pharmaceutical Co Ltd Anticuerpo anti-receptor de il-6.
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
WO2009072604A1 (ja) * 2007-12-05 2009-06-11 Chugai Seiyaku Kabushiki Kaisha 抗nr10抗体、およびその利用
US8431127B2 (en) 2007-12-05 2013-04-30 Chugai Seiyaku Kabushiki Kaisha Method for treating pruritus comprising administering an NR10 antagonist

Patent Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP0058481A1 (en) 1981-02-16 1982-08-25 Zeneca Limited Continuous release pharmaceutical compositions
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
JPH0159878B2 (ja) 1982-05-21 1989-12-20 Yunibaashitei Obu Karifuorunia
EP0133988A2 (de) 1983-08-02 1985-03-13 Hoechst Aktiengesellschaft Regulatorische Peptide enthaltende pharmazeutische Präparate mit protrahierter Freisetzung und Verfahren zu deren Herstellung
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
EP0239400A2 (en) 1986-03-27 1987-09-30 Medical Research Council Recombinant antibodies and methods for their production
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1995001438A1 (en) 1993-06-30 1995-01-12 Medical Research Council Sbp members with a chemical moiety covalently bound within the binding site; production and selection thereof
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1998046777A1 (fr) 1997-04-11 1998-10-22 Centre National De La Recherche Scientifique (Cnrs) Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
WO2000075314A1 (fr) 1999-06-02 2000-12-14 Chugai Research Institute For Molecular Medicine, Inc. Proteine receptrice d'hemopoietine
WO2003104453A1 (ja) 2002-06-05 2003-12-18 中外製薬株式会社 抗体作製方法
WO2005005636A1 (ja) 2003-07-15 2005-01-20 Chugai Seiyaku Kabushiki Kaisha 形質転換細胞によるIｇMの産生とその定量方法
WO2006088956A2 (en) 2005-02-14 2006-08-24 Zymogenetics, Inc. Methods of predicting therpeutic response in atopic dermatitis to il-31 antagonists
WO2006088955A2 (en) 2005-02-14 2006-08-24 Zymogenetics, Inc. Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
WO2006088855A1 (en) * 2005-02-14 2006-08-24 Zymogenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
WO2006122079A1 (en) 2005-05-06 2006-11-16 Zymogenetics, Inc. Il-31 monoclonal antibodies and methods of use

Non-Patent Citations (46)

* Cited by examiner, † Cited by third party
Title
"A novel type I cytokine receptor is expressed on monocytes, signals proliferation, and activates STAT-3 and STAT-5", J BIOL CHEM, vol. 277, 2002, pages 16831 - 6
"Administration of anti-interleukin 18 antibody fails to inhibit development of dermatitis in atopic dermatitis-model mice NC/Nga.", BRITISH JOURNAL OF DERMATOLOGY, vol. 149, 2003, pages 39 - 45
"GPL, a novel cytokine receptor related to GP130 and leukemia inhibitory factor receptor", J BIOL CHEM, vol. 278, 2003, pages 49850 - 9
"IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis.", J ALLERGY CLIN IMMUNOL., vol. 117, no. 2, February 2006 (2006-02-01), pages 418 - 25
"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice", NAT IMMUNOL, vol. 5, 2004, pages 752 - 60
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10
BETTER ET AL., SCIENCE, vol. 240, 1988, pages 1041 - 1043
BETTER, M.; HORWITZ, A. H., METHODS ENZYMOL., vol. 178, 1989, pages 476 - 496
BIOCHEM. BIOPHYS. RES. COMMUN., vol. 228, 1996, pages 838 - 45
BIRD, R. E.; WALKER, B. W., TRENDS BIOTECHNOL., vol. 9, 1991, pages 132 - 137
CLIN IMMUNOL, vol. 108, 2003, pages 257 - 262
CO, M. S. ET AL., J. IMMUNOL., vol. 152, 1994, pages 2968 - 2976
DALBADIE-MCFARLAND, G. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 79, 1982, pages 6409 - 13
DILLON SR ET AL.: "Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice", NAT IMMUNOL., vol. 5, no. 7, July 2004 (2004-07-01), pages 752 - 60
FASEB J., vol. 6, 1992, pages 2422 - 2427
HASHIMOTO-GOTOH, T; MIZUNO, T; OGASAHARA, Y; NAKAGAWA, M.: "An oligodeoxyribonucleotide-directed dual amber method for site-directed mutagenesis", GENE, vol. 152, 1995, pages 271 - 275
HOPP, T. P., BIOTECHNOLOGY, vol. 6, 1988, pages 1204 - 1210
HUSTON, J. S. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 85, 1988, pages 5879 - 5883
INT ARCH ALLERGY IMMUNOL, vol. 133, 2004, pages 55 - 63
J BIOL CHEM, vol. 277, 2002, pages 16831 - 6
J BIOL CHEM, vol. 278, 2003, pages 49850 - 9
J IMMUNOL, vol. 171, 2003, pages 5507 - 5513
KARLIN; ALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 7
KOHLER, G.; MILSTEIN, C., METHODS ENZYMOL., vol. 73, 1981, pages 3 - 46
KOHLER. G.; MILSTEIN, C., METHODS ENZYMOL., vol. 73, 1981, pages 3 - 46
KRAMER W; FRITZ HJ: "Oligonucleotide-directed construction of mutations via gapped duplex DNA Methods", ENZYMOL., vol. 154, 1987, pages 350 - 367
KRAMER, W; DRUTSA, V; JANSEN, HW; KRAMER, B; PFLUGFELDER, M; FRITZ, HJ: "The gapped duplex DNA approach to oligonucleotide-directed mutation construction", NUCLEIC ACIDS RES., vol. 12, 1984, pages 9441 - 9456
KUNKEL, TA: "Rapid and efficient site-specific mutagenesis without phenotypic selection", PROC NATL ACAD SCI USA., vol. 82, 1985, pages 488 - 492
LAMOYI, E., METHODS ENZYMOL., vol. 121, 1986, pages 652 - 663
LANGER, CHEM. TECH., vol. 12, 1982, pages 98 - 105
LANGER, J. BIOMED. MATER. RES., vol. 15, 1981, pages 167 - 277
LEI, S. P. ET AL., J. BACTERIOL., vol. 169, 1987, pages 4379
MARK, D. F. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 5662 - 6
MIZUSHIMA ET AL., NUCLEIC ACIDS RES., vol. 18, 1990, pages 5322
MULLIGAN ET AL., NATURE, vol. 277, 1979, pages 108
NAT IMMUNOL, vol. 5, 2004, pages 752 - 60
NUCLEIC ACIDS. RES., vol. 18, no. 17, 1990, pages 5322
PLUCKTHUN, A.; SKERRA, A., METHODS ENZYMOL., vol. 178, 1989, pages 497 - 515
PROTEIN ENGINEERING, vol. 9, no. 3, 1996, pages 299 - 305
ROUSSEAUX, J. ET AL., METHODS ENZYMOL., vol. 121, 1986, pages 663 - 669
SATO, K. ET AL., CANCER RES., vol. 53, 1993, pages 851 - 856
SIDMAN, BIOPOLYMERS, vol. 22, 1983, pages 547 - 56
WANG, A. ET AL., SCIENCE, vol. 224, 1984, pages 1431 - 3
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546
ZOLLER, M. J.; SMITH, M., NUCLEIC ACIDS RES., vol. 10, 1982, pages 6487 - 500
ZOLLER, MJ; SMITH, M.: "Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors", METHODS ENZYMOL., vol. 100, 1983, pages 468 - 500

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US9745378B2 (en) 2006-06-08 2017-08-29 Chugai Seiyaku Kabushiki Kaisha Antibodies that bind to cytokine receptor NR10
US9028821B2 (en) 2006-06-08 2015-05-12 Chugai Seiyaku Kabushiki Kaisha Method of treating an inflammatory disease comprising administering an NR 10 antibody antagonist
US11332533B2 (en) 2007-09-26 2022-05-17 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
US9828429B2 (en) 2007-09-26 2017-11-28 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US12122840B2 (en) 2007-09-26 2024-10-22 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9688762B2 (en) 2007-09-26 2017-06-27 Chugai Sciyaku Kabushiki Kaisha Modified antibody constant region
US11248053B2 (en) 2007-09-26 2022-02-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US12116414B2 (en) 2007-09-26 2024-10-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US8431127B2 (en) 2007-12-05 2013-04-30 Chugai Seiyaku Kabushiki Kaisha Method for treating pruritus comprising administering an NR10 antagonist
US9399680B2 (en) 2007-12-05 2016-07-26 Chugai Seiyaku Kabushiki Kaisha Nucleic acids encoding anti-NR10 antibodies
US11371039B2 (en) 2008-04-11 2022-06-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US10472623B2 (en) 2008-04-11 2019-11-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US11359194B2 (en) 2008-04-11 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US9890377B2 (en) 2008-04-11 2018-02-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US9868948B2 (en) 2008-04-11 2018-01-16 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
JP5139517B2 (ja) * 2008-12-05 2013-02-06 中外製薬株式会社 抗ｎｒ１０抗体、およびその利用
EP2354161A4 (en) * 2008-12-05 2013-01-02 Chugai Pharmaceutical Co Ltd ANTIBODY AGAINST NR10 AND APPLICATION THEREOF
JPWO2010064697A1 (ja) * 2008-12-05 2012-05-10 中外製薬株式会社 抗ｎｒ１０抗体、およびその利用
EP2354161A1 (en) * 2008-12-05 2011-08-10 Chugai Seiyaku Kabushiki Kaisha Anti-nr10 antibody, and use thereof
WO2010064697A1 (ja) * 2008-12-05 2010-06-10 中外製薬株式会社 抗nr10抗体、およびその利用
EP2949672A1 (en) * 2008-12-05 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Anti-nr10 antibody, and use thereof
US10253091B2 (en) 2009-03-19 2019-04-09 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US10066018B2 (en) 2009-03-19 2018-09-04 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EA028899B1 (ru) * 2010-04-30 2018-01-31 Алексион Фармасьютикалз, Инк. АНТИ-C5a-АНТИТЕЛА И СПОСОБЫ ПРИМЕНЕНИЯ АНТИТЕЛ
US9221901B2 (en) 2010-04-30 2015-12-29 Alexion Pharmaceuticals, Inc. Methods of treating complement-associated disorders with anti-C5a antibodies
US9963503B2 (en) 2010-04-30 2018-05-08 Alexion Pharmaceuticals, Inc. Methods of producing anti-C5a antibodies
WO2011137395A1 (en) * 2010-04-30 2011-11-03 Rother Russell P Anti-c5a antibodies and methods for using the antibodies
US9469690B2 (en) 2010-04-30 2016-10-18 Alexion Pharmaceuticals, Inc. Methods of treating complement-associated disorders with anti-C5a antibodies
US9011852B2 (en) 2010-04-30 2015-04-21 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies
US9434784B1 (en) 2010-04-30 2016-09-06 Alexion Pharmaceuticals, Inc. Nucleic acids encodng anti-C5A antibodies
US11407821B2 (en) 2010-04-30 2022-08-09 Alexion Pharmaceuticals, Inc. Anti-C5A antibodies
US10450370B2 (en) 2010-04-30 2019-10-22 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies
US9371378B1 (en) 2010-04-30 2016-06-21 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies
US9309310B2 (en) 2010-04-30 2016-04-12 Alexion Pharmaceuticals, Inc. Nucleic acids encoding anti-C5a antibodies
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
KR20230043246A (ko) 2015-04-14 2023-03-30 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
US11773173B2 (en) 2015-04-14 2023-10-03 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
KR20240033097A (ko) 2015-04-14 2024-03-12 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
KR20210145295A (ko) 2015-04-14 2021-12-01 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
US10544227B2 (en) 2015-04-14 2020-01-28 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
US11260125B2 (en) 2019-11-20 2022-03-01 Chugai Seiyaku Kabushiki Kaisha Anti-IL31RA antibody-containing formulations
US11723976B2 (en) 2019-11-20 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Methods of administering anti-IL31A antibody-containing formulations
US12171830B2 (en) 2019-11-20 2024-12-24 Chugai Seiyaku Kabushiki Kaisha Anti-IL-31RA antibody-containing formulations
WO2022049614A1 (ja) 2020-09-01 2022-03-10 中外製薬株式会社 Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物

Also Published As

Publication number Publication date
AU2008332276A1 (en) 2009-06-11
BRPI0821145A2 (pt) 2015-06-16
RU2010127291A (ru) 2012-01-10
EP2241332A1 (en) 2010-10-20
MX2010006097A (es) 2010-08-04
BRPI0821145B8 (pt) 2021-05-25
JPWO2009072598A1 (ja) 2011-04-28
TW200932265A (en) 2009-08-01
AU2008332276B2 (en) 2014-02-27
RU2596397C2 (ru) 2016-09-10
EP2241332A4 (en) 2011-01-26
RU2541780C2 (ru) 2015-02-20
CA2708065A1 (en) 2009-06-11
BRPI0821145B1 (pt) 2019-10-15
CN101939025B (zh) 2015-03-25
JP5475460B2 (ja) 2014-04-16
US20100310556A1 (en) 2010-12-09
MY185647A (en) 2021-05-27
US8431127B2 (en) 2013-04-30
HK1200697A1 (en) 2015-08-14
CA2708065C (en) 2015-02-24
TWI441649B (zh) 2014-06-21
RU2014150548A (ru) 2015-07-20
HK1151226A1 (en) 2012-01-27
KR20100100935A (ko) 2010-09-15
CN101939025A (zh) 2011-01-05
CN104162155A (zh) 2014-11-26
KR101595134B1 (ko) 2016-02-17
MY162546A (en) 2017-06-15

Similar Documents

Publication Publication Date Title
WO2009072598A1 (ja) 掻痒症治療剤
WO2011088120A8 (en) Antibody formulation and therapeutic regimens
WO2009072604A1 (ja) 抗nr10抗体、およびその利用
WO2012062925A3 (en) Compounds and methods for treating pain
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
WO2008051805A3 (en) Triazolo-pyridazine protein kinase modulators
MX2020012426A (es) Anticuerpos anti-cd38.
WO2009136976A3 (en) Il-17ra-il-17rb antagonists and uses thereof
WO2011133795A3 (en) Beta-carbolines as inhibitors of haspin and dyrk kinases
NZ589764A (en) NMDA receptor antagonists for the treatment of neuropsychiatric disorders
CL2014001452A1 (es) Compuestos derivados de dihidro-benzo-oxacina y dihidro-pirido-oxacina; composicion farmaceutica; metodo para modular la actividad de enzimas pi3k; metodo para el tratamiento; y uso para el tratamiento de artritis reumatoide, pénfigo vulgar, esclerosis multiple, miastenia grave, alergia y malaria, entre otras enfermedades.
WO2012071509A3 (en) Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
WO2012040636A3 (en) Compounds and methods for treating diseases mediated by protease activated receptors
WO2011038933A3 (en) Anti-hsv antibody
WO2007135026A3 (de) Substituierte pteridine als therapeutika
WO2012156023A8 (en) Process for producing inorganic particulate material
EP2976125A4 (en) SYSTEMS AND METHOD FOR PRODUCING A CONTROLLED MIXTURE FOR HYPERTHERMIC TREATMENT
MX2014002394A (es) Inhibidores de rock suaves, novedosos.
WO2014080286A3 (en) Methods and compositions for treating multiple sclerosis and related disorders
WO2012131001A3 (en) Cushion for patient interface
IL200091A0 (en) Use of chitosans for the treatment of nail inflammatory diseases
MY173491A (en) Therapeutic or prophylactic agent for biliary tract diseases
WO2007098967A3 (en) Imidazole compounds having pharmaceutical activity towards the sigma receptor
WO2008099913A1 (ja) ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤
WO2012067899A3 (en) Foxa1 as a marker for invasive bladder cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880126534.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08857461

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009544731

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 3862/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12010501271

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/006097

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008332276

Country of ref document: AU

Ref document number: 2708065

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008332276

Country of ref document: AU

Date of ref document: 20081205

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107014699

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010127291

Country of ref document: RU

Ref document number: 2008857461

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PI 2010002563

Country of ref document: MY

WWE Wipo information: entry into national phase

Ref document number: 12746229

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0821145

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100607